By Nana O 
High-grade glioma, a particularly aggressive form of brain cancer affecting both children and adults, presents a formidable therapeutic challenge. Its insidious nature is amplified by the critical and often inaccessible locations of tumors within the brain, a high incidence of recurrence even after initial treatment, and the significant hurdle of the blood-brain barrier, which impedes the delivery of many promising drug candidates. Despite these obstacles, a significant breakthrough may be on the horizon, thanks to a groundbreaking collaborative effort between researchers from the University of Michigan, Dana Farber Cancer Institute, and the Medical University of Vienna. Their collective work, recently published in the esteemed journal Cancer Cell, illuminates a novel and potentially transformative therapeutic strategy targeting a specific genetic alteration within these devastating tumors.
Unlocking a Genetic Vulnerability: The Role of PDGFRA
At the heart of this promising development lies the gene PDGFRA (platelet-derived growth factor receptor alpha). This gene plays a crucial role in cell growth and division, and alterations within its DNA sequence are frequently implicated in the development and progression of high-grade gliomas. Recognizing PDGFRA as a common culprit, the research team strategically focused their efforts on identifying drugs capable of effectively inhibiting its aberrant activity. This approach is particularly significant because, beyond conventional treatments like surgery and radiation, effective pharmacological interventions for high-grade gliomas, especially upon recurrence, remain scarce.
The research team embarked on an extensive screening process, evaluating a range of commercially available drugs known to inhibit PDGFRA. Their meticulous investigation yielded a standout candidate: avapritinib. This drug demonstrated remarkable potency and specificity in targeting PDGFRA alterations, distinguishing itself as a frontrunner for further investigation.
Avapritinib: A Drug with Proven Potential and a Key Advantage
Avapritinib is not an entirely novel entity in the therapeutic landscape. It has already earned approval from the United States Food and Drug Administration (FDA) for specific indications, including the treatment of gastrointestinal stromal tumors (GIST) harboring a PDGFRA exon 18 mutation, as well as advanced, indolent, and systemic mastocytosis. This existing regulatory approval provides a crucial advantage, suggesting a foundation of safety and efficacy data that can accelerate its potential application in a new disease context.
However, the path to treating brain tumors is often fraught with the challenge of drug delivery. The blood-brain barrier acts as a highly selective gatekeeper, preventing many molecules from entering the central nervous system. For avapritinib to be a viable option for high-grade glioma, it needed to demonstrate its ability to penetrate this critical barrier.
Crossing the Divide: Avapritinib’s Blood-Brain Barrier Penetration
The research team’s findings regarding avapritinib’s ability to cross the blood-brain barrier were met with considerable excitement. "When we gave mice the drug and showed that it reached the brain, we knew we were onto something," explained Kallen Schwark, a U-M M.D./Ph.D. student and one of the study’s lead authors. This crucial observation, corroborated by collaborators at Dana Farber Cancer Institute and the Medical University of Vienna, signaled a significant stride forward. The drug’s capacity to enter the brain opens up a realistic pathway for it to exert its therapeutic effects directly on tumor cells within the central nervous system.
Dr. Carl Koschmann, a key figure in the research and the ChadTough Defeat DIPG Research Professor at the University of Michigan, echoed this sentiment. "We were excited to see that avapritinib essentially shut off PDGFRA signaling in mouse brain tumors," he stated. This preclinical validation in animal models provided compelling evidence of avapritinib’s potential to disrupt the oncogenic pathways driven by PDGFRA mutations in high-grade gliomas.
From Preclinical Promise to Clinical Application: Early Patient Successes
Buoyed by the preclinical data, the research team recognized the urgent need to translate these findings into tangible patient benefits. While a formal clinical trial was not yet fully established, they leveraged an expanded access program, facilitated by Blueprint Medicines (the developer of avapritinib), to treat the first cohort of patients with high-grade glioma. This initiative represented a critical step in bridging the gap between laboratory discovery and clinical application, offering hope to individuals with limited treatment options.
"Across multiple international institutions, we treated the first eight patients with high-grade glioma with avapritinib," Dr. Koschmann reported. The initial results from this early cohort were encouraging. "The patients tolerated the drug well and in three of the eight patients, we were able to see their tumors shrink." While a tumor shrinkage rate of approximately 37.5% in this small group is a preliminary finding, it represents a significant achievement and a powerful indicator of the drug’s potential therapeutic activity in human patients.
Laying the Foundation for Future Trials and Broader Impact
These promising early clinical observations, combined with the robust preclinical data, provided a strong scientific rationale for further clinical investigation. This evidence was instrumental in paving the way for the inclusion of pediatric high-grade glioma in a Phase I pediatric solid tumor trial. This trial has since completed patient accrual, and the analysis of its results is currently underway. The outcomes of this trial are eagerly anticipated, as they will provide more comprehensive data on avapritinib’s safety and efficacy in a larger pediatric patient population.
The broader implications of this research extend beyond the immediate application of avapritinib. The success in targeting a key oncogenic pathway in brain tumors with a drug that effectively penetrates the blood-brain barrier is a significant scientific advancement. "We have very few examples of drugs entering brain tumors like this and shutting down key oncogenic pathways," Dr. Koschmann emphasized. "These results support a lot of ongoing efforts to build on the success of avapritinib and other brain-penetrant small molecule inhibitors." This work serves as a testament to the power of targeted therapy and the ongoing pursuit of novel drug development strategies for challenging cancers.
The Complex Landscape of High-Grade Glioma and the Path Forward
High-grade gliomas are notoriously difficult to treat, characterized by aggressive growth, a poor prognosis with a median survival of less than two years for many, and a limited arsenal of effective therapies. The recurrence rate is high, often leading to disease progression and further therapeutic challenges. The challenges posed by the tumor’s location and the blood-brain barrier have historically made drug development for these cancers a particularly arduous undertaking.
While the findings regarding avapritinib offer a beacon of hope, the researchers are acutely aware that a single drug is unlikely to be a panacea for such a complex disease. "We know a single drug is not going to be enough for this disease," Dr. Koschmann stated pragmatically. The future of treating high-grade glioma likely lies in a multifaceted approach, involving the judicious combination of different therapeutic modalities.
The research team is already looking ahead, exploring strategies that build upon the success of avapritinib. Their immediate next step involves investigating the synergistic potential of combining avapritinib with other targeted therapies, such as MAP kinase inhibitors. "We already have a follow-up story on targeting avapritinib with MAP kinase inhibitors that we are just as excited about," Dr. Koschmann revealed, underscoring their commitment to developing comprehensive treatment strategies. This ongoing research aims to leverage the initial gains made with avapritinib to create more potent and durable responses, ultimately improving outcomes for patients facing this devastating diagnosis.
The collaborative spirit that underpins this research, bringing together expertise from leading institutions, is a crucial element in accelerating scientific discovery and translating it into clinical impact. The journey from identifying a genetic vulnerability to developing a drug that can effectively target it within the complex environment of the brain is a long and intricate one. However, the recent advancements with avapritinib represent a significant milestone, offering renewed optimism in the fight against high-grade glioma.
